Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients
The anti-CD38 monoclonal antibody daratumumab had a favorable safety profile with manageable infusion-related reactions, according to results from a phase 2 study of multiple myeloma patients who had been treated with three or more prior therapies. Peter M. Voorhees, MD, discusses the results.